Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
absence, aimed, ataxia, aumolertinib, begun, BID, copy, cORR, CR, CRs, dataset, Economy, edema, elevation, elzovantinib, EQRx, GCN, Helsinn, IMT, intermediate, landscape, liver, longest, magnitude, Peripheral, RANO, regression, rescind, sarcoma, SFM, titration, uPR, vertigo
Removed:
certainty, District, ending, exert, Northern, proceed, relying, spend, subset, xenograft
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view